Twelve of these AML patients displayed IDH mutations: 8/12 AML IDH-mutant AMLs at day 30 displayed a VAF < 2.5% and 4/12> 2.5%; all the IDH-mutant AML patients with a VAF > 2.5% pertain to the group of AML patients with a short event-free survival [107]. Here, IDH2 is linked to acute myeloid leukemia.